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Tissue engineered heart valves based on human cells
Abstract
Valvular heart disease is still a significant cause of morbidity and mortality worldwide. Clinically used
valve replacements including mechanical valves as well as fixed biological xeno- or homografts are
associated with several major disadvantages. Alternatively, tissue engineering aims at the fabrication of
autologous living cardiovascular replacements with the potential to grow and to repair, particularly for
paediatric applications. Therefore, autologous cells are harvested and seeded onto three-dimensional
matrices followed by biomimetic in vitro conditioning enabling the development of the neo-heart valve
tissue. Here, we review different human cell sources such as vessels, bone marrow, umbilical cord tissue
and blood, and chorionic villi with particular regard to cell phenotypes and their suitability for
extracellular matrix production for tissue engineering purposes.
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Valvular heart disease is still a significant cause
of morbidity and mortality worldwide. Clinically
used valve replacements including mechanical
valves as well as fixed biological xeno- or homo-
grafts are associated with several major disadvan-
tages. Alternatively, tissue engineering aims at the
fabrication of autologous living cardiovascular 
replacements with the potential to grow and to
repair, particularly for paediatric applications.
Therefore, autologous cells are harvested and
seeded onto three-dimensional matrices followed
by biomimetic in vitro conditioning enabling the
development of the neo-heart valve tissue. Here,
we review different human cell sources such as ves-
sels, bone marrow, umbilical cord tissue and blood,
and chorionic villi with particular regard to cell
phenotypes and their suitability for extracellular
matrix production for tissue engineering purposes. 
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Progress in medical treatment of cardiovascu-
lar diseases and defects has been significant; par-
ticularly tissue substitution has shown that func-
tional replacements of tissue and organs could be
lifesaving. In the United States, for example,
60,000 heart valve replacements are performed an-
nually [1]. Nevertheless, heart valve disease is still
a significant cause of morbidity and mortality
worldwide and leads in approximately 20,000 cases
per year to death [1]. Furthermore, 60% of substi-
tute valve recipients develop serious prosthesis-
related complications within 10 years postopera-
tively [2]. Thromboembolisms as well as increased
rates of infections and immunological reactions
against the foreign material are the major prob-
lems with currently available heart valve replace-
ments, which are either artificial valves or chemi-
cally treated biological xeno- or homografts. Often
lifelong anti-coagulation therapy is necessary, bur-
dened with a substantial risk of spontaneous bleed-
ing and embolism, particularly in patients over 
70 years [3]. 
Remaining inherently different from the tis-
sue it replaces, the currently available prostheses
do not actively adapt to the physiological environ-
ment such as to pressure changes and mechanical
demands as they represent non-living materials.
Furthermore, when implanted into the immature
heart of a child, these materials do not grow with
the paediatric patient, which is a disadvantage for
the repair of congenital defects. Regarding this
major limitation, there is a special need for living,
growing cardiovascular replacements for paedi-
atric applications. Paediatric treatment of cardiac
defects commonly requires non-autologous valves
or conduits [4, 5] with many disadvantages includ-
ing obstructive tissue ingrowths and calcification
of the replacements [6]. This typically causes re-
operations over the lifetime of paediatric patients
with cardiovascular defects, associated with in-
creasing morbility and mortality. Living tissue 
replacements with the capacity of growth and re-
generation would have fundamental advantages
over the currently available cardiovascular replace-
ments. 
The above mentioned limitations have moti-
vated the exploration of novel approaches towards
valve replacement. A series of studies have been
undertaken to determine if tissue engineering
principles could be used to develop viable, valve
substitutes with a thromboresistant surface and a
viable interstitium with repair, remodelling and
growth capabilities. Several groups demonstrated
the feasibility of creating living cardiovascular
structures by cell seeding on synthetic polymers,
collagen, or xenogeneic scaffolds [7–10]. As to
heart valve tissue engineering the first milestone
was the successful replacement of a single pul-
monary valve leaflet by a tissue engineered autol-
ogous leaflet [11]. 
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Two strategies have been used to generate liv-
ing autologous heart valve replacements. One re-
quires an in vitro phase generating the replacement
ex vivo [12]. The other bypasses the in vitro tissue
culture phase by direct implantation of natural tis-
sue-derived heart valve matrices for potential cell
ingrowth and remodelling in vivo [13]. Matrices
used for the latter approach included decellu-
larised tissues derived from pericardium or valves,
cell free porcine small intestine submucosa [13] or
synthetic biodegradable polymeric scaffold such as
collagen or fibrin gel. However, decellularised
scaffolds implanted in humans demonstrated in-
growth of host cells, no calcification but a strong
inflammatory response [14]. The structural failure
of these materials inhibited further use.
Strategies in heart valve tissue engineering
Scaffold Source Examples Reference
synthetic biocompatible polyglycolic acid (PGA) Shinoka T, et al., Circulation 1996
and biodegradable polylactic acid (PLA) Shinoka T, et al., JTCS 1998
polymers polyhydroxyalkanoates (P3HB) Sodian R, et al., Circulation 2000
PGA and PLA (PGLA) Zund G, et al., EJCTS 1997 
PGA and P4HB Hoerstrup SP, et al., Circulation 2000
biological xenogenic or decellularized porcine pulmonary heart valves Schenke-Layland K, et al.
allogenic pulmonary heart valves on allogenic acellular Cardiovasc Research 2003
matrix conduits Steinhoff G, et al., Circulation 2000
gels fibrin heart valves based on fibrin-myofibroblast cell suspension Jockenhövel S, et al., EJCTS 2001
hybrid decellularised heart porcine aortic heart valves dip coated Stamm C, et al., Ann Thorac Surg 2004
valves coated with with biodegradable poly(hydroxybutyrate)
synthetic polymer
Following the approach of in vitro tissue engi-
neering, the successful fabrication of autologous
living cardiovascular replacements similar to their
native counterparts is supported by three main el-
ements: (1) autologous cells that resemble their na-
tive counterparts in phenotype and functionality,
(2) a temporary supporter matrix (biodegradable
scaffold) which promotes tissue strength until the
extracellular matrix produced by the autologous
cells guarantees functionality on its own, and (3)
culture conditions enabling tissue formation and
maturation by in vitro conditions similar to a phys-
iological environment.
Figure 1 summarises the concept of in vitro
tissue engineering. Concretely, in a first step cells
are harvested from an autologous donor structure.
After expansion in vitro, cells are seeded onto a
biodegradable heart valve scaffold, which should
ideally be at least 90% porous [15]. Scaffolds could
be fabricated from polymers and the use of these
different synthetic materials has already been
broadly demonstrated for cardiovascular tissue en-
gineering. An overview about the most common
scaffold types applied in cardiovascular tissue en-
gineering is given in table 1. After seeding, the 
constructs are cultured in nutrient media supple-
mented with ascorbic acid and 10% foetal calf
serum in a pulse duplicator in vitro system (bio-
reactor) mimicking the in vivo environment. In
order to improve cell migration, proliferation and
extracellular matrix production mechanical load
by means of shear stress have been applied to 
the seeded valves in pulsatile flow bioreactors
[16–18]. There, the tissue formation takes place
and after several days the constructs are ready for
implantation.
This concept for in vitro heart valve tissue en-
gineering was earlier applied in an animal model
using completely autologous tissue engineered
heart valves based on polyglycolic acid coated with
poly-4-hydroxybutyrate (PGA/P4HB) (figure 2)
starter matrices [9]. In this “proof of principle”
study trileaflet heart valve scaffolds were fabricated
from PGA/P4HB bioabsorbable polymers and 
sequentially seeded with autologous ovine myo-
fibroblasts and endothelial cells. The constructs
were grown for 14 days in a pulse duplicator in vitro
system under gradually increasing flow and 
pressure conditions and implanted into a growing
sheep model (n = 6 lambs; mean weight at cell 
Concept of in vitro heart valve tissue engineering
Figure 1
Concept of in vitro
heart valve tissue 
engineering. Auto-
logous cells are 
harvested from the
patient and expanded
in vitro (1). When 
sufficient numbers
are reached, cells are
seeded onto a
biodegradable heart
valve scaffold (2).
Constructs are posi-
tioned in a bioreactor
(3) and conditioned.
When tissue forma-
tion is sufficient, 
tissue engineered
heart valves are
ready for implanta-
tion (4).
Table 1
Examples of 
different scaffolds 
for heart valve 
tissue engineering.
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harvest 9 ± 2.8 kg). Echocardiography demon-
strated mobile, functioning leaflets without steno-
sis, thrombus or aneurysm. These autologous 
tissue engineered valves functioned up to 5 months
in vivo and resembled normal heart valves as to 
microstructure, mechanical properties and extra-
cellular matrix formation.
Figure 2
Example of 
a biodegradable 
scaffold (PGA/P4HB)
before seeding.
Human cell source Cardiovascular construct Reference
dermal fibroblast (covered with bovine endothelium) valve leaflets Sinoka T, et al. Ann Thorac Surg 1995;
Circulation 1996
foreskin fibroblast (covered with human endothelial)  Patch Zund G, et al. EJCTS  1998
marrow stromal cells trileaflet heart valve Hoerstrup SP, et al. Circulation 2002
aortic myofibroblasts patch/trileaflet heart valve Ye Q, et al, EJCTS 2000
Jockenhoevel S, et al. EJCTS 2001
aortic myofibroblasts and venous cells Patch Hoerstrup SP, et al. ASAIO 2002
Schnell A, et al. Thorac Cardiovasc Surg 2001
venous myofibroblast Leaflets Mol A, et al. Thorac Cardiovasc Surg 2003
umbilical cord myofibroblast from vein pulmonary artery conduits Hoerstrup SP, et al. Ann Thorac Surg 2002
umbilical cord  myofibroblast Patch Schmidt D, et al. EJCTS 2005
(covered with human endothelial cells derived 
from umbilical cord blood endothelial progenitor cell) 
chorionic villi-derived cells Leaflets Schmidt D, et al. Circulation 2006
(covered with human endothelial cells derived 
from umbilical cord blood endothelial progenitor cell)
Table 2
Examples of different
cell sources for 
heart valve tissue 
engineering.
Following extensive studies using ovine vascu-
lar derived cells [9, 19, 20] and regarding future
human application the suitability of human cells
derived from various human cell sources have been
investigated. Among the most promising are vas-
cular-derived cells, bone marrow-derived cells,
blood-derived cells, umbilical cord-derived cells
and chorionic villi-derived cells, particularly for
paediatric application (table 2). 
Human vascular-derived cells
Experiments with human aortic myofibro-
blasts and endothelial cells demonstrated easy iso-
lation and in vitro culture [9, 21]. Sequentially
seeded on biodegradable scaffolds, the human aor-
tic cells showed layered tissue formation [22]. Cells
from saphenous veins showed comparable excel-
lent growth properties and tissue formation after
seeding on biodegradable scaffolds as aortic cells
[23] and mammary artery cells (unpublished data).
Saphenous vein cells can be obtained by a minor
surgical intervention in local anaesthesia and
therefore represent an attractive cell source for
cardiovascular tissue engineering. In recent exper-
iments we studied the influence of the cell donor
age on the suitability of human myofibroblasts 
derived from saphenous vein for tissue engineer-
ing purposes. Neither the growth as monolayer
cell culture nor the  three-dimensional growth as
tissue engineered constructs was influenced by the
age of the cell donor (unpublished data). Extracel-
lular matrix protein production and mechanical
properties of the tissue engineered constructs 
were comparable among the different age groups 
(unpublished data). Based on these results we 
conclude that the cardiovascular tissue engineer-
Evaluation of human cell sources for tissue engineered heart valves 
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ing concept may be independent of cell donor age 
and therefore be suitable also for elder patient 
populations. 
Human marrow stromal cells
With regard to future routine clinical realisa-
tion of the tissue engineering concept, human
marrow stromal cells are a promising cell source.
In contrast to vascular cells, these cells can be ob-
tained without surgical interventions representing
an easy-to-access cell source in a possible routine
clinical scenario. The usage of marrow stromal
cells may offer several advantages in i) easy collec-
tion by a simple bone marrow puncture avoiding
the sacrifice of intact vascular structures, ii) show-
ing the potential to differentiate into multiple 
cell lineages, and iii) demonstrating unique im-
munological characteristics allowing persistence
in allogenic settings. Recently, human marrow
stromal cells have been used for the fabrication of
trileaflet heart valves (figure 3) [24]. Histology 
of the tissue engineered valve leaflets revealed 
viable tissue organised in a layered fashion with ex-
tracellular matrix proteins characteristic of heart
valve tissue such as collagen I and III, and gly-
cosaminoglycans. However, the typical three-
layered structural composition of native valve
leaflets comprising a ventricularis, spongiosa and
fibrosa layer was not achieved. The ultra-struc-
tural analysis of the tissue engineered heart 
valves supported this observation demonstrating
cell elements typical of viable, secretionally active
myofibroblasts such as actin/myosin filaments as
well as collagen fibrils and elastin. The quantita-
tive extracellular matrix protein analysis revealed
values significantly lower compared to human 
native valve tissue. 
Human umbilical cord-derived cells
In order to provide tissue engineered con-
structs for congenital heart defects, alternative cell
sources have been investigated, with particular at-
tention to preserving the intact donor structure of
the newborn patients. Human umbilical cords are
readily available, easy to obtain and by means of
modern cell and tissue banking technologies they
might be used as an individual cell pool for the pa-
tient’s lifetime. Furthermore, the presence of mes-
enchymal progenitor cells in the Wharton’s jelly of
human umbilical cords with multilineage potential
[25, 26] and the possibility to obtain these cells pre-
natally using ultrasound guided sampling technol-
ogy make this cell source even more attractive. In
culture, human umbilical cord cells demonstrated
excellent growth properties. Recently, umbilical
cord-derived cells have been successfully utilised
to generate paediatric tissues in vitro demonstrat-
ing excellent production of extracellular matrix
[27, 28].
Blood derived endothelial progenitor cells
It has been shown that the presence of en-
dothelium on heart valves reduces the risk for both
coagulation and inflammatory complications.
Therefore, to improve the functional capacities,
the tissue engineered heart valve constructs are
covered with a layer of autologous human en-
dothelial cells. Endothelial cells from different 
vascular sources have been investigated demon-
strating promising results [21, 22]. When typical
endothelial antigen expression of endothelial cells
from different sources including arteria radialis,
arteria mammaria, vena saphena, umbilical cord
was compared by flowcytometry, no significant
cell-source dependent differences were detected
(unpublished data). Also functional assays such as
adhesion assays using peripheral blood-derived
mononuclear cells have shown comparable func-
tionality (unpublished data). However, the harvest
of endothelial cells from vessels requires an inva-
sive procedure. Furthermore, for paediatric appli-
cation prenatal endothelial cell harvest from ves-
sels would not be possible without substantial risks
for the unborn child. Blood-derived endothelial
progenitor cells are an attractive alternative cell
source as they can be isolated from peripheral
blood as well as from umbilical cord blood. The
Figure 3
Tissue engineered
trileaflet heart valve
based on human
stromal cells.
Reprinted with 
permission from: 
Hoerstrup SP, et al.
Circulation.
2002;106:I-143–50.
Figure 4
Umbilical cord blood-
derived endothelial
progenitor cells. 
21 days after isola-
tion, endothelial pro-
genitor cells demon-
strated cobble-stone
morphology (A) and
up-take for acetylated
human Low Density
Lipoprotein (ac-LDL;
B). Furthermore, cells
showed endothelial
phenotype express-
ing cluster of differ-
entiation 31 (CD31; 
C) and von Wille-
brand factor (vWF;
D). Reprinted with
permission from:
Schmidt D, et al. 
Ann Thorac Surg.
2002;78:2094–8.
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latter one can already be obtained during preg-
nancy using the well-established method of ultra-
sound guided percutaneous blood sampling. Thus,
harvesting endothelial progenitor cells prior birth
is possible without substantial risks. The feasibil-
ity of using human umbilical cord blood-derived
endothelial progenitor cells for tissue engineering
of cardiovascular replacements for paediatric ap-
plication has been demonstrated (figure 4) [27, 28].
When differentiated endothelial progenitor cells
were co-cultured with non-endothelial cells as well
as when exposed to mechanical stimuli they
showed stabile phenotypes [29]. The extracellular
matrix production of undifferentiated endothelial
progenitor cells was demonstrated to be insuffi-
cient whereas the differentiation into endothelial
cells on biodegradable scaffolds was observed [30].
In the overall tissue engineering concept, endo-
thelial progenitor cells represent a promising cell
source for the endothelialisation of heart valves.
Since endothelial progenitor cells are easily acces-
sible current research aims at their transdifferen-
tation into myofibroblast cells in order to enable
blood as a sole cell source for paediatric applica-
tions. 
Chorionic villi-derived cells
Of particular importance is cell-harvesting at
early perinatal stage that allows having the tissue-
engineered replacement ready for implantation at
the birth of the patient in order to prevent second-
ary damage to the immature heart. As prenatal tis-
sue harvest from human placenta by chorionic villi
sampling is already a routine procedure for prena-
tal genetic diagnostics the human placenta repre-
sents a promising prenatal cell source. Particularly,
its chorionic villi provide extra-embryonically sit-
uated foetal mesenchymal cells including pro-
genitor cells. The obtained tissue samples could 
also serve as a cell source for tissue engineering.
Theoretically, one specimen could then be used 
for both diagnostics and the tissue engineering 
application. Recently, the successful use of chori-
onic villi-derived myofibroblast-fibroblast like
cells obtained from routine prenatal tissue sam-
pling combined with umbilical cord blood-
derived endothelial progenitor cells for heart valve
tissue engineering has been demonstrated [31].
The generated heart valve tissues showed cell 
phenotypes similar to their native counterparts
and production of glycoaminoglycans and collagen
as major extracellular matrix elements of native
heart valves.
Limitations 
Besides a few occasional pilot studies based 
on decellularised heart valves [14, 32] no systemic 
evidence that the heart valve tissue engineering
concept can be applied in the clinical routine has
been reported so far. However, as shown by Simon
et al. [14] some of the decellularised scaffolds im-
planted in humans exhibited a strong inflamma-
tory response resulting in dramatic failure. 
Regarding the use of biodegradable scaffolds,
local inflammation and systemic toxicity due to
degradation products is a possible problem. Fur-
thermore, there is a potential risk that ex vivo treat-
ment of cells or the use of immature cells such as
progenitors might lead to tumour development 
by uncontrolled cell growth or differentiation via
genetic alterations. Future in vivo studies will focus
on these important aspects.
In summary, various cells seem to be suitable
for tissue engineering purposes. Among the 
most promising are progenitor cells either ob-
tained from bone marrow, umbilical cord or 
chorionic villi, particularly for paediatric appli-
cations. This review was undertaken to provide
more detailed understanding of cell phenotype and 
extracellular matrix development during the tissue
engineering process, in order to define quality 
criteria for future clinical use. Although having
first indications as to the influence of age, cell
sources and in vitro conditions, knowledge on bio-
chemical and immunological characteristics of 
the cells / tissues undergoing in vitro growth is still
very limited. In addition, little is known about 
the influence of endothelial cells on extracellular
matrix formation and on the quality of in vitro
engineered tissue. 
However, heart valve tissue engineering is a
promising approach for living, functional autolo-
gous replacements. Particularly paediatric patients
will benefit from growing replacement materials
for the repair of congenital heart defects. Never-
theless, before clinical application of the tissue 
engineering heart valve concept will be routine
several issues will have to be addressed. 
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